<DOC>
	<DOCNO>NCT02279862</DOCNO>
	<brief_summary>The purpose study examine safety effectiveness ( well drug work ) two different dos ( 3 mg/kg 10 mg/kg ) Ipilimumab ( Yervoyâ„¢ ) patient metastatic castration resistant prostate cancer .</brief_summary>
	<brief_title>Safety Efficacy Study Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive</brief_title>
	<detailed_description>Prostate Cancer Clinical Trials Working Group 2 ( PCWG2 ) Response Evaluation Criteria In Solid Tumors ( RECIST )</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Prostate cancer metastasis Prostate cancer castration resistant Progression hormonal therapy Visceral metastasis ( eg liver , lung brain metastasis ) Prior treatment immunotherapy prostate cancer Prior ongoing cytotoxic therapy prostate cancer Autoimmune disease Inadequate hematologic , renal , hepatic function</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>